Target Price | $61.20 |
Price | $62.84 |
Deviation |
2.61%
register free of charge
|
Number of Estimates | 26 |
26 Analysts have issued a price target Guardant Health, Inc. 2026 .
The average Guardant Health, Inc. target price is $61.20.
This is
2.61%
register free of charge
$73.50
16.96%
register free of charge
$20.20
67.85%
register free of charge
|
|
A rating was issued by 34 analysts: 31 Analysts recommend Guardant Health, Inc. to buy, 2 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Guardant Health, Inc. stock has an average upside potential 2026 of
2.61%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 739.02 | 948.04 |
31.04% | 28.28% | |
EBITDA Margin | -54.29% | -23.92% |
41.33% | 55.94% | |
Net Margin | -59.05% | -41.64% |
30.55% | 29.48% |
28 Analysts have issued a sales forecast Guardant Health, Inc. 2025 . The average Guardant Health, Inc. sales estimate is
This results in the following potential growth metrics:
25 Analysts have issued an Guardant Health, Inc. EBITDA forecast 2025. The average Guardant Health, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
29 Guardant Health, Inc. Analysts have issued a net profit forecast 2025. The average Guardant Health, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.56 | -3.17 |
16.82% | 10.96% | |
P/E | negative | |
EV/Sales | 8.78 |
29 Analysts have issued a Guardant Health, Inc. forecast for earnings per share. The average Guardant Health, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Guardant Health, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Barclays |
Locked
➜
Locked
|
Locked | Oct 02 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Sep 26 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
Leerink Partners |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
Mizuho |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
Wolfe Research |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
Analyst Rating | Date |
---|---|
Locked
Barclays:
Locked
➜
Locked
|
Oct 02 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Sep 26 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Sep 25 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
Sep 25 2025 |
Locked
Leerink Partners:
Locked
➜
Locked
|
Sep 25 2025 |
Locked
Mizuho:
Locked
➜
Locked
|
Sep 25 2025 |
Locked
Wolfe Research:
Locked
➜
Locked
|
Sep 25 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.